Trilaciclib hydrochloride
CAS No. 1977495-97-8
Trilaciclib hydrochloride ( G1T28 hydrochloride )
Catalog No. M22845 CAS No. 1977495-97-8
Trilaciclib hydrochloride is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).Incubation with Trilaciclib hydrochloride (G1T28) for 24 hours can induce a strong G1 cell cycle arrest (time=0). Cells have re-entered the cell cycle and demonstrate cell-cycle kinetics similar to untreated control cells By 16 hours after Trilaciclib hydrochloride washout.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 411 | In Stock |
|
10MG | 599 | In Stock |
|
50MG | 1314 | In Stock |
|
100MG | 1773 | In Stock |
|
200MG | 2394 | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTrilaciclib hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionTrilaciclib hydrochloride is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).Incubation with Trilaciclib hydrochloride (G1T28) for 24 hours can induce a strong G1 cell cycle arrest (time=0). Cells have re-entered the cell cycle and demonstrate cell-cycle kinetics similar to untreated control cells By 16 hours after Trilaciclib hydrochloride washout.
-
DescriptionTrilaciclib hydrochloride is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).Incubation with Trilaciclib hydrochloride (G1T28) for 24 hours can induce a strong G1 cell cycle arrest (time=0). Cells have re-entered the cell cycle and demonstrate cell-cycle kinetics similar to untreated control cells By 16 hours after Trilaciclib hydrochloride washout. These results demonstrate that Trilaciclib hydrochloride causes a transient, and reversible G1 arrest. A transient Trilaciclib hydrochloride-mediated G1 cell-cycle arrest in CDK4/6-sensitive cells decreases the in vitro toxicity of a variety of commonly used cytotoxic chemotherapy agents associated with myelosuppression.G1T28 inhibits the phosphorylation of RB and induces an exclusive, reversible G1 arrest.n vivo, G1T28 reversibly and in a dose-dependent manner, regulates the proliferation of HSPCs.?Pretreatment of mice with oral G1T28 allows for the faster recovery of CBCs following chemotherapy treatment.?Likewise, oral G1T28 does not protect RB-deficient tumors from chemotherapy but adds to the antitumor effect.?Although this effect was found in athymic mice that lack T lymphocytes, it is still possible that the enhanced efficacy is due to preservation of other immune cell types such as natural killer cells.?
-
SynonymsG1T28 hydrochloride
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCdk4/cyclin D1;cdk6/cyclin D3
-
Research Areacancer
-
IndicationColorectal Cancer Metastatic|Myelosuppression Adult|Chemotherapeutic Toxicity
Chemical Information
-
CAS Number1977495-97-8
-
Formula Weight519.47
-
Molecular FormulaC24H32Cl2N8O
-
Purity>98% (HPLC)
-
SolubilityH2O:25.64 mg/mL (49.36 mM; ultrasonic and adjust pH to 2 with HCl); DMSO:1.1 mg/mL (2.12 mM; Need ultrasonic)
-
SMILESO=C1C2=CC3=CN=C(NC4=CC=C(N5CCN(C)CC5)C=N4)N=C3N2C6(CCCCC6)CN1.[H]Cl.[H]Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Bisi JE, et al. Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Mol Cancer Ther. 2016 May;15(5):783-93.
molnova catalog
related products
-
JSH-150
JSH-150 (JSH150) is a potent, highly selective inhibitor of CDK9 kinase with IC50 of 1 nM in the biochemical assays, displays 300-10000-fold selectivity over other CDK kinase family members (CDK7 IC50=1.72 uM).
-
Dinaciclib
A potent and selective CDK inhibitor with IC50 of 1, 1, 3 and 4 nM against CDK2, CDK5, CDK1 and CDK9, respectively.
-
Ryuvidine
Ryuvidine is a potent, selective CDK4 inhibitor with IC50 of 6.0 uM, displays >30-fold selectivity over CDK2 (IC50>100 uM).